Vestal Point Capital’s KalVista Pharmaceuticals KALV Stock Holding History

Vestal Point Capital’s Portfolio KALV Stock Details KALV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$37.2M	Sell	1,850,000 -40,000	-2%	-$645K	1.04%	33
2025 Q4	$30.5M	Buy	1,890,000 +1,140,000	+152%	+$15.1M	1.04%	31
2025 Q3	$9.13M	Sell	750,000 -3,925,000	-84%	-$54.2M	0.41%	53
2025 Q2	$52.9M	Sell	4,675,000 -76,292	-2%	-$933K	2.78%	10
2025 Q1	$54.8M	Sell	4,751,292 -18,708	-0.4%	-$191K	3.92%	6
2024 Q4	$40.4M	Buy	4,770,000 +770,000	+19%	+$7.97M	2.4%	14
2024 Q3	$46.3M	Buy	4,000,000 +1,700,000	+74%	+$21.4M	3.51%	7
2024 Q2	$27.1M	Buy	2,300,000 +1,645,000	+251%	+$19.2M	2.02%	14
2024 Q1	$7.77M	Buy	+655,000	New	+$8.73M	0.64%	33

Other funds holding KALV

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

SCM

Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Vestal Point Capital's KALV Position: Q1 2026 in Review

Vestal Point Capital reduced its KalVista Pharmaceuticals (KALV) stake by 2.1% in Q1 2026, selling an estimated $645K and leaving 1,850,000 shares worth $37.2M. The position accounts for 1.04% of the portfolio, ranked #33.

Vestal Point Capital first reported a position in KALV in Q1 2024 and has held it in 9 quarters since. The position peaked at $54.8M in Q1 2025. 183 funds tracked by Wall St. Rank hold KALV as of Q1 2026.

Vestal Point Capital held 1,850,000 shares of KalVista Pharmaceuticals worth $37.2M as of Q1 2026.
Vestal Point Capital sold 40,000 KalVista Pharmaceuticals shares in Q1 2026, an estimated $645K.
KalVista Pharmaceuticals made up 1.04% of Vestal Point Capital's portfolio in Q1 2026, its #33 holding.
Vestal Point Capital first reported a position in KalVista Pharmaceuticals in Q1 2024 and has held it in 9 quarters since.
Vestal Point Capital's KalVista Pharmaceuticals position peaked at $54.8M in Q1 2025.
183 funds tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q1 2026.

Based on Vestal Point Capital's 13F filing for Q1 2026, filed 15 May 2026.